{"pmid":32359090,"title":"Convalescent plasma: possible therapy for novel coronavirus disease 2019.","text":["Convalescent plasma: possible therapy for novel coronavirus disease 2019.","Transfusion","Cao, Huiling","Shi, Yuan","32359090"],"journal":"Transfusion","authors":["Cao, Huiling","Shi, Yuan"],"date":"2020-05-03T11:00:00Z","year":2020,"_id":"32359090","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/trf.15797","topics":["Treatment"],"weight":1,"_version_":1666138495319539715,"score":9.490897,"similar":[{"pmid":32296259,"pmcid":"PMC7158785","title":"Convalescent plasma: A possible treatment of COVID-19 in India.","text":["Convalescent plasma: A possible treatment of COVID-19 in India.","In India, SARS-CoV-2 virus-induced coronavirus disease 2019 (COVID-19) has already infected close to 5500 people, causing the death of 164. While these numbers are not comparable with values observed for the USA, Italy, or Spain, given the population of India, and the fact that the pandemic is now in an exponential stage of growth, the risks of a contagion that affects a large sector of the Indian population are real. There are no current effective strategies to prevent the spread, other than minimizing contact through social distancing, while no fully effective drugs to prevent or treat COVID-19 exist, although several candidate drugs and repurposed antiviral and immune-modulating pharmacotherapies are being tested or in compassionate use. One postexposure prophylaxis, convalescent (immune) plasma (CP), has shown some success in China and previously in the cure and therapy of other coronaviruses, SARS-1 and Middle East respiratory syndrome. Drawn from current patients who are infected with COVID-19, its CP (human anti-SARS-CoV-2 plasma) might be one way to modulate the infectivity of this virus or its effects postinfection.","Med J Armed Forces India","Teixeira da Silva, Jaime A","32296259"],"abstract":["In India, SARS-CoV-2 virus-induced coronavirus disease 2019 (COVID-19) has already infected close to 5500 people, causing the death of 164. While these numbers are not comparable with values observed for the USA, Italy, or Spain, given the population of India, and the fact that the pandemic is now in an exponential stage of growth, the risks of a contagion that affects a large sector of the Indian population are real. There are no current effective strategies to prevent the spread, other than minimizing contact through social distancing, while no fully effective drugs to prevent or treat COVID-19 exist, although several candidate drugs and repurposed antiviral and immune-modulating pharmacotherapies are being tested or in compassionate use. One postexposure prophylaxis, convalescent (immune) plasma (CP), has shown some success in China and previously in the cure and therapy of other coronaviruses, SARS-1 and Middle East respiratory syndrome. Drawn from current patients who are infected with COVID-19, its CP (human anti-SARS-CoV-2 plasma) might be one way to modulate the infectivity of this virus or its effects postinfection."],"journal":"Med J Armed Forces India","authors":["Teixeira da Silva, Jaime A"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32296259","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.mjafi.2020.04.006","keywords":["antibodies","asia","respiratory disease","sars-cov-2 virus"],"locations":["India","USA","Italy","Spain","India","Indian","China","India"],"countries":["India","Spain","China","United States","Italy"],"countries_codes":["IND|India","ESP|Spain","CHN|China","USA|United States","ITA|Italy"],"topics":["Treatment"],"weight":1,"_version_":1666138493202464768,"score":55.179268},{"pmid":32219429,"title":"Convalescent Plasma to Treat COVID-19: Possibilities and Challenges.","text":["Convalescent Plasma to Treat COVID-19: Possibilities and Challenges.","JAMA","Roback, John D","Guarner, Jeannette","32219429"],"journal":"JAMA","authors":["Roback, John D","Guarner, Jeannette"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32219429","source":"PubMed","week":"202013|Mar 23 - Mar 29","doi":"10.1001/jama.2020.4940","topics":["Treatment"],"weight":1,"_version_":1666138492301737985,"score":50.686123},{"pmid":32380316,"pmcid":"PMC7198427","title":"Convalescent plasma in Covid-19: Possible mechanisms of action.","text":["Convalescent plasma in Covid-19: Possible mechanisms of action.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible of the coronavirus disease 2019 (COVID-19) pandemic. Therapeutic options including antimalarials, antivirals, antibiotics and vaccines are under study. Meanwhile the current pandemic has called attention over old therapeutic tools to treat infectious diseases. Convalescent plasma (CP) constitutes the first option in the current situation, since it has been successfully used in other coronaviruses outbreaks. Herein, we discuss the possible mechanisms of action of CP and their repercussion in COVID-19 pathogenesis, including direct neutralization of the virus, control of an overactive immune system (i.e., cytokine storm, Th1/Th17 ratio, complement activation) and immunomodulation of a hypercoagulable state. All these benefits of PC are expected to be better achieved if used in non-critically hospitalized patients, in the hope of reducing morbidity and mortality.","Autoimmun Rev","Rojas, Manuel","Rodriguez, Yhojan","Monsalve, Diana M","Acosta-Ampudia, Yeny","Camacho, Bernardo","Gallo, Juan Esteban","Rojas-Villarraga, Adriana","Ramirez-Santana, Carolina","Diaz-Coronado, Juan C","Manrique, Ruben","Mantilla, Ruben D","Shoenfeld, Yehuda","Anaya, Juan-Manuel","32380316"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible of the coronavirus disease 2019 (COVID-19) pandemic. Therapeutic options including antimalarials, antivirals, antibiotics and vaccines are under study. Meanwhile the current pandemic has called attention over old therapeutic tools to treat infectious diseases. Convalescent plasma (CP) constitutes the first option in the current situation, since it has been successfully used in other coronaviruses outbreaks. Herein, we discuss the possible mechanisms of action of CP and their repercussion in COVID-19 pathogenesis, including direct neutralization of the virus, control of an overactive immune system (i.e., cytokine storm, Th1/Th17 ratio, complement activation) and immunomodulation of a hypercoagulable state. All these benefits of PC are expected to be better achieved if used in non-critically hospitalized patients, in the hope of reducing morbidity and mortality."],"journal":"Autoimmun Rev","authors":["Rojas, Manuel","Rodriguez, Yhojan","Monsalve, Diana M","Acosta-Ampudia, Yeny","Camacho, Bernardo","Gallo, Juan Esteban","Rojas-Villarraga, Adriana","Ramirez-Santana, Carolina","Diaz-Coronado, Juan C","Manrique, Ruben","Mantilla, Ruben D","Shoenfeld, Yehuda","Anaya, Juan-Manuel"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32380316","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.autrev.2020.102554","keywords":["ace-2 receptor","covid-19","convalescent plasma","coronavirus","cytokines","intravenous immunoglobulins","neutralizing antibodies","sars-cov-2"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666597097357443072,"score":50.686123},{"pmid":32467007,"title":"Successful treatment of a centenarian with coronavirus disease 2019 (COVID-19) using convalescent plasma.","text":["Successful treatment of a centenarian with coronavirus disease 2019 (COVID-19) using convalescent plasma.","BACKGROUND: Because treatment options for coronavirus disease 2019 (COVID-19) are very limited, the use of convalescent plasma has bee explored. CASE PRESENTATION AND TREATMENT: A male centenarian with cough and dyspnea for 2 months was diagnosed with COVID-19. Without effective treatments and with the increased risks of antiviral therapy for the elderly, this patient was given convalescent plasma. The viral load, complete blood count, inflammatory indicators, vital signs, and clinical symptoms were observed before and after COVID-19 convalescent plasma transfusion. RESULTS: After convalescent plasma transfusion, significant improvement was observed on laboratory indicators and clinical symptoms of the patient. Concurrently, SARS-CoV-2 viral load decreased sharply after the first transfusion (from 2.55 x 104 to 1.39 x 103 copies/mL) and became undetectable after the second transfusion. CONCLUSIONS: With the substantial increase of COVID-19 in recent months,treatment for elderly patients has become restricted in some countries. The successful treatment of this 100-year-old patient using convalescent plasma suggests that we should consider adding convalescent plasma in th management of the elderly.","Transfus Apher Sci","Kong, Yujie","Cai, Chen","Ling, Li","Zeng, Li","Wu, Meihong","Wu, Yanyun","Zhang, Wei","Liu, Zhong","32467007"],"abstract":["BACKGROUND: Because treatment options for coronavirus disease 2019 (COVID-19) are very limited, the use of convalescent plasma has bee explored. CASE PRESENTATION AND TREATMENT: A male centenarian with cough and dyspnea for 2 months was diagnosed with COVID-19. Without effective treatments and with the increased risks of antiviral therapy for the elderly, this patient was given convalescent plasma. The viral load, complete blood count, inflammatory indicators, vital signs, and clinical symptoms were observed before and after COVID-19 convalescent plasma transfusion. RESULTS: After convalescent plasma transfusion, significant improvement was observed on laboratory indicators and clinical symptoms of the patient. Concurrently, SARS-CoV-2 viral load decreased sharply after the first transfusion (from 2.55 x 104 to 1.39 x 103 copies/mL) and became undetectable after the second transfusion. CONCLUSIONS: With the substantial increase of COVID-19 in recent months,treatment for elderly patients has become restricted in some countries. The successful treatment of this 100-year-old patient using convalescent plasma suggests that we should consider adding convalescent plasma in th management of the elderly."],"journal":"Transfus Apher Sci","authors":["Kong, Yujie","Cai, Chen","Ling, Li","Zeng, Li","Wu, Meihong","Wu, Yanyun","Zhang, Wei","Liu, Zhong"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32467007","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.transci.2020.102820","keywords":["coronavirus disease 2019","convalescent plasma","transfusion"],"e_drugs":["Thorium"],"topics":["Treatment"],"weight":1,"_version_":1668167109871403008,"score":45.658688},{"pmid":32305026,"pmcid":"PMC7146649","title":"Challenges of Convalescent Plasma Therapy on COVID-19.","text":["Challenges of Convalescent Plasma Therapy on COVID-19.","J Clin Virol","Zhao, Qian","He, Yong","32305026"],"journal":"J Clin Virol","authors":["Zhao, Qian","He, Yong"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32305026","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jcv.2020.104358","topics":["Treatment"],"weight":1,"_version_":1666138491066515456,"score":45.047516}]}